MX348369B - Virus oncolítico de sarampión. - Google Patents

Virus oncolítico de sarampión.

Info

Publication number
MX348369B
MX348369B MX2013001930A MX2013001930A MX348369B MX 348369 B MX348369 B MX 348369B MX 2013001930 A MX2013001930 A MX 2013001930A MX 2013001930 A MX2013001930 A MX 2013001930A MX 348369 B MX348369 B MX 348369B
Authority
MX
Mexico
Prior art keywords
measles virus
suicide gene
encoding
invention pertains
cytosine deaminase
Prior art date
Application number
MX2013001930A
Other languages
English (en)
Other versions
MX2013001930A (es
Inventor
M Lauer Ulrich
Bitzer Michael
Lampe Johanna
Zimmermann Martina
Berchtold Susanne
lange Sebastian
J Neubert Wolfgang
Bossow Sascha
Original Assignee
Bossow Sascha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bossow Sascha filed Critical Bossow Sascha
Publication of MX2013001930A publication Critical patent/MX2013001930A/es
Publication of MX348369B publication Critical patent/MX348369B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18471—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende un virus recombinante de sarampión que comprende un gen suicida para usarse en el tratamiento de células malignas con resistencias primaria o secundaria contra un virus oncolítico de sarampión sin actividad de gen suicida, en donde dicho virus recombinante de sarampión es de cepa Schwarz de la vacuna de sarampión, en donde dicho gen suicida comprende una fusión de una citosina desaminasa y una uracilo fosforribosiltransferasa, y en donde dicho virus recombinante de sarampión comprende una secuencia de ARN de acuerdo con la SEQ-ID NO.4, SEQ-ID NO.8, o SEQ-ID NO. 9.
MX2013001930A 2010-08-20 2011-08-19 Virus oncolítico de sarampión. MX348369B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10008726A EP2420242A1 (en) 2010-08-20 2010-08-20 Oncolytic measles virus
PCT/EP2011/004200 WO2012022495A1 (en) 2010-08-20 2011-08-19 Oncolytic measles virus

Publications (2)

Publication Number Publication Date
MX2013001930A MX2013001930A (es) 2014-02-27
MX348369B true MX348369B (es) 2017-06-08

Family

ID=43589508

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001930A MX348369B (es) 2010-08-20 2011-08-19 Virus oncolítico de sarampión.

Country Status (8)

Country Link
US (2) US9272008B2 (es)
EP (2) EP2420242A1 (es)
JP (1) JP6001535B2 (es)
CN (1) CN103200947A (es)
BR (1) BR112013003892A8 (es)
ES (1) ES2540526T3 (es)
MX (1) MX348369B (es)
WO (1) WO2012022495A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2759301A1 (en) * 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
GB2583296A (en) 2015-01-05 2020-10-21 Seagull Biosolutions Pvt Ltd Dna molecules producing custom designed replicating and non-replicating negative stranded rna viruses and uses there of
JP7007720B2 (ja) 2018-03-07 2022-01-25 株式会社オクジュー 保持具並びにこれを用いた間仕切壁及び間仕切壁の施工方法
EP3957650A1 (en) 2020-08-17 2022-02-23 Themis Bioscience GmbH Co-stimulatory 4-1bbl ectodomain polypeptides for immunomodulation
CN113293148B (zh) * 2021-03-10 2022-10-25 上海青赛生物科技有限公司 一种h基因替换的嵌合麻疹减毒株的构建
WO2023250055A1 (en) * 2022-06-23 2023-12-28 Merck Sharp & Dohme Llc Immunogenic compositions for herpes simplex virus proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3045581B2 (ja) 1991-10-14 2000-05-29 社団法人北里研究所 麻疹ワクチンウイルス株同定方法
DE69510207T3 (de) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
JP2000517194A (ja) 1996-09-27 2000-12-26 アメリカン・サイアナミド・カンパニー モノネガビラレス（Ｍｏｎｏｎｅｇａｖｉｒａｌｅｓ）と称される目のウイルスにおける弱毒化の原因となる３’ゲノムプロモーター領域およびポリメラーゼ遺伝子の突然変異
BR9909076A (pt) 1998-03-26 2000-12-05 American Cyanamid Co Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b
ES2330309T3 (es) 2002-06-20 2009-12-09 Institut Pasteur Adnc infeccioso de una cepa de vacuna aprobada de virus del sarampion. uso para composiciones inmunogenicas.

Also Published As

Publication number Publication date
EP2605783A1 (en) 2013-06-26
US9795643B2 (en) 2017-10-24
ES2540526T3 (es) 2015-07-10
US20130217757A1 (en) 2013-08-22
BR112013003892A2 (pt) 2020-01-21
WO2012022495A1 (en) 2012-02-23
US9272008B2 (en) 2016-03-01
BR112013003892A8 (pt) 2021-02-02
JP6001535B2 (ja) 2016-10-05
US20150250838A1 (en) 2015-09-10
MX2013001930A (es) 2014-02-27
EP2420242A1 (en) 2012-02-22
CN103200947A (zh) 2013-07-10
JP2013538202A (ja) 2013-10-10
EP2605783B1 (en) 2015-03-25

Similar Documents

Publication Publication Date Title
MX348369B (es) Virus oncolítico de sarampión.
WO2013036795A3 (en) Oncolytic herpes simplex virus and therapeutic uses thereof
WO2014011901A3 (en) Methods and compositions for delivery of biologics
EA024121B9 (ru) Композиции эндорибонуклеаз и способы их использования
EP2171078A4 (en) ENABLING THE USE OF LONG DSRNA FOR GENE TARGETING IN MAMMALIAN CELLS AND OTHER SELECTED ANIMAL CELLS
WO2011005799A3 (en) Rna containing modified nucleotides and use thereof in vaccines
WO2012106377A3 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
WO2012072096A8 (en) Method for cellular rna expression
WO2013188638A3 (en) Endoribonucleases and methods of use thereof
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
MX2016006620A (es) Receptores de células t humanas con alta afinidad modificados por medio de manipulación genetica.
MX359398B (es) Compuestos para transduccion viral mejorada.
PH12021550173A1 (en) Improved thymidine kinase gene
EP3967329A4 (en) AGAINST BCMA GM IMMUNE CELLS AND THEIR USE
MX2013007657A (es) Oligodesoxinucleotidos inmunoestimulantes.
IN2015DN02546A (es)
NZ703701A (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
IN2012DN03209A (es)
WO2014026110A3 (en) Compounds for improved viral transduction
AP3277A (en) Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases
GB2453475A (en) Live vaccine strains of francisella
WO2011119716A3 (en) Flavivirus host range mutations and uses thereof
WO2012028961A3 (en) Compositions and methods for treating friedreich's ataxia with interferon gamma
HK1162599A1 (en) An infectious recombinant cloning system of duck enteritis virus vaccine strain, construction method and use thereof
WO2012037215A3 (en) Recombinant yeast with improved ethanol tolerance and related methods of use

Legal Events

Date Code Title Description
FG Grant or registration